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Objective: We investigated the efficacy of rifabutin (RFB)-containing regimens for the treat-
ment of RFB-susceptible, multidrug-resistant tuberculosis (MDR-TB).
Methods: From 146 patients diagnosed with MDR-TB between January 2006 and December 2009
at Asan Medical Center in South Korea, 31 patients (21.2%) were found to have RFB-susceptible
MDR-TB. Of these 31 patients, 14 patients who had been treated with RFB for more than one
month were included. Forty-two patients with RFB-resistant MDR-TB were selected as a control
group, and the outcomes of both groups were retrospectively compared.
Results: Of 14 patients with RFB-susceptible MDR-TB, the mean age was 44.4 years and the
proportion of extensively drug-resistant TB (XDR-TB) was 35.7% (5/14). Baseline characteristics
and the drug resistance pattern (except RFB) did not differ between the two groups. Treat-
ment success was achieved in 12 (85.7%) patients in the RFB group: cure in 10 (71.4%) and
treatment completion in two (14.3%). The treatment success rate was 52.4% (22/42) in the
control group (p Z 0.032). Treatment failure was more common in patients of the control
group (40.5% vs. 14.3%; p Z 0.106).
Conclusions: RFB is useful as an additional drug in the treatment of MDR-TB in patients with
RFB-susceptible MDR-TB.
ª 2012 Elsevier Ltd. All rights reserved.3010 3892; fax: þ82 2 3010 6968.
.kr (T.S. Shim).
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Multidrug-resistant tuberculosis (MDR-TB) affects people in
all regions of the world and remains a serious threat to
public health.1 In addition, the appearance of extensively
drug-resistant TB (XDR-TB), a subset of MDR-TB, has
complicated both the treatment and control of the
disease.2 In South Korea, an intermediate TB-burden
country, 2.7% of patients newly diagnosed with TB and
14% of patients with a history of previous TB treatment
were found to have MDR-TB in 2004.3 Additionally, XDR-TB
is estimated to occur in approximately 5e10% of the
patients with MDR-TB.4 In South Korea, the overall treat-
ment success rate has been reported to be 45.3% among
1407 patients with MDR-TB and only 29.3% among patients
diagnosed with XDR-TB.5 Despite the global effort to
control MDR-TB, few new drugs have been developed to
treat it since 1970.
Rifabutin (RFB) is a first-line anti-TB drug which is
reserved for patients with drug-susceptible TB and who are
taking medications incompatible with rifampicin (RIF), such
as antiretroviral drugs.6,7 Although RFB may have compa-
rable rates of cure and relapse as those of RIF in the
treatment of drug-susceptible TB,8,9 few data on the effi-
cacy of RFB in the treatment of MDR-TB are available.10,11
Although the level of cross-resistance between RIF and
RFB has been reported to be approximately 90%,12,13 it is
known to be relatively low in South Korea, with as many as
20e30% of patients with RFB-susceptible MDR-TB.14,15 Thus,
RFB might be a successful drug for the treatment of
a subset of MDR-TB. However, to date there has not been
any study conducted to address this issue in South Korea.
Therefore, we retrospectively investigated the role of RFB
in the treatment of RFB-susceptible MDR-TB.Methods
Study subjects
Because drug susceptibility testing (DST) to RFB began in
South Korea in 2006, our study subjects were selected from
the MDR-TB registry of Asan Medical Center between
January 2006 and December 2009. A total of 146 patients
were diagnosed with MDR-TB during this period. Among
them, 31 (21.2%) had RFB-susceptible TB, of whom 15 were
treated with RFB-containing regimens. The baseline clinical
characteristics and drug resistance patterns did not differ
between the 15 RFB users and the 16 RFB non-users (data
not shown). Among these 15 patients, one was excluded
based on less than one month of treatment with RFB due to
an adverse event (severe myalgia), leaving 14 patients with
RFB-susceptible MDR-TB enrolled. The patients’ medical
records, TB treatment history with regard to World Health
Organization (WHO) guidelines, DST results, treatment
modality, and outcomes were retrospectively reviewed.
Using a nested case-control design, we selected 42
subjects from patients with MDR-TB whose DST showed
resistance to RFB during the same period to be the control
group. This ensured both groups would have an identical
drug resistance pattern except for RFB.Definitions of study measures
Classifications of drug resistance pattern
Four groups were defined as follows5: (1) XDR-TB was
defined as MDR-TB with bacillary resistance to any one of
the fluoroquinolones (FQ) and to at least one of three,
second-line injectable drugs (SLID, i.e. amikacin, capreo-
mycin, or kanamycin); (2) pre-XDR-TBFQ as MDR-TB resis-
tant to any FQ; (3) pre-XDR-TBSILD as MDR-TB resistant to at
least one SLID; and (4) other MDR-TB as MDR-TB not resis-
tant to both FQ and SLID.
Treatment outcomes
Six treatment outcome categories, i.e. cure, treatment
completion, treatment failure, transfer out, default, and
death were defined.16 Treatment success was defined as
either cure or treatment completion. As recommended by
the WHO, all treatment outcomes were based on AFB (acid-
fast bacillus) culture results. The duration of adequate
treatment was defined as 18 months or more and 12 months
or more after culture conversion.
Radiologic severity
Radiographic severity was estimated using the recommen-
dations of the National Tuberculosis Association of the
United States.17
Drug susceptibility tests
Conventional DST was performed using the absolute
concentration method with Lowe¨nsteineJensen (LJ) media
for isoniazid, RIF, ethambutol, pyrazinamide, strepto-
mycin, kanamycin, cycloserine, p-aminosalicylic acid, pro-
thionamide, ofloxacin, and moxifloxacin at the Korean
Institute of Tuberculosis, South Korea’s supranational TB
reference laboratory. The critical concentration level of
RFB was set at 20 mg/mL, which is a half the value of RIF
(40 mg/mL). Growth greater than 1% of the control was
regarded as drug resistance.15
Statistical analysis
All analyses were performed using SPSS software (version
12.0, SPSS Inc., Chicago, IL, USA). Comparisons between
the RFB group and the control group were made using
ManneWhitney tests for continuous variables and c2 test or
the Fisher’s exact test for categorical variables. All tests of
significance were two sided; p < 0.05 was considered
statistically significant.
Results
Characteristics of study subjects
Of the 14 patients in the RFB group, five (35.7%) were
defined as having XDR-TB, six (42.9%) with pre-XDR-TBFQ,
one (7.1%) with pre-XDR-TBSILD, and two (14.3%) with other
MDR-TB. The 42 patients in the control group had the same
proportion of drug-resistance pattern as that of the RFB
group (Table 1). Baseline characteristics such as age, sex,
Table 1 Drug resistance pattern of 56 patients with MDR-
TB.




XDR-TB 5 (35.7) 15 (35.7)
pre-XDR-TBFQ 6 (42.9) 18 (42.9)
pre-XDR-TBSILD 1 (7.1) 3 (7.1)
Other MDR TB 2 (14.3) 6 (14.3)
Abbreviations: RFB Z rifabutin; XDR Z extensively drug-
resistant; TB Z tuberculosis; FQ Z fluoroquinolones;
SLID Z second-line injectable drugs; MDR Z multi-drug-resis-
tant.
Values are number (%).
294 K.-W. Jo et al.previous history of TB treatment, and radiologic severity
were comparable in the two groups. Human immunodefi-
ciency virus (HIV) tests were conducted on five (8.9%)
patients with none showing positive results (Table 2).
Patients who were not tested for HIV did not have any
clinical indications of HIV infection at initiation of treat-
ment or during follow-up. The resistance rates for all anti-
TB drugs were similar between the two groups except for
RFB (Table 3).
Treatment modalities and drug tolerance
All patients in both groups were treated using individual-









Previous history of TB treatment
History of TB treatment with first-line drugs only
History of TB treatment with second-line drugs
2 previous TB treatments
Family history of TB
Extrapulmonary TB
HIV seropositive (n Z 5)







Abbreviations: RFB Z rifabutin; BMI Z body mass index; TB Z tube
bacillus.
Values are mean  SD or number (%).
a ‘Other’ includes hypertension (n Z 1), chronic pancreatitis (n Zhistory of previous TB drug regimen. All 14 patients
received 300 mg/day of RFB with a mean duration of RFB
treatment of 518.4 (204.2) days and a median duration of
RFB treatment of 537 (range 235e832) days.
All 14 patients in the RFB group tolerated RFB well,
without any adverse events. In the case of other drugs,
each one patient of two (14.3%) in the RFB group did not
tolerate either prothionamide or p-aminosalicylic acid,
respectively. In the control group eight patients (19.0%) had
adverse events to various other drugs:prothionamide
(nZ 3), p-aminosalicylic acid (nZ 2), kanamycin (nZ 2),
and pyrazinamide (n Z 1).
Surgical resection of pulmonary lesion was performed on
six patients (10.7%) out of a total of 56 patients, without
a statistically significant difference between the two
groups (Table 4). The median number of total prescribed
drugs and drugs active against TB was significantly higher in
patients in the RFB group (Table 4). However, when RFB was
not counted, no significant differences were found between
the two groups. Although the use of linezolid was higher in
the RFB group, it did not show a significant difference
(Table 4).
Treatment outcomes
Treatment success was achieved in 12 (85.7%) patients in
the RFB group: cure in 10 (71.4%) and treatment completion
in two (14.3%). The treatment success rate was 52.4% (22/
42) in the control group (pZ 0.032). Treatment failure was





44.4  14.2 41.7  15.6 0.438
7/7 19/23 0.757
19.4  2.9 21.7  4.1 0.175
0.333
1 (7.1) 7 (16.7)
0 2 (4.8)
0 3 (7.1)
8 (57.1) 26 (61.9) 0.136
5 (35.7) 15 (35.7) 1.000
6 (42.9) 19 (45.2) 0.954
4 (28.6) 12 (28.6) 1.000
0 1 (2.4) 1.000
0/1 (0.0) 0/4 (0.0) 1.000
14 (100) 36 (85.7) 0.319
0.314
8 (57.1) 27 (64.3)
3 (21.4) 3 (7.1)
3 (21.4) 12 (28.6)
6 (42.9) 22 (52.4) 0.537
4 (28.6) 19 (45.2) 0.355
rculosis; HIV Z human immunodeficiency virus; AFB Z acid-fast
1), and chronic renal disease (n Z 1).
Table 3 Drug resistance rate at treatment initiation.





Pyrazinamide 11 (78.6) 31 (73.8) 1.000
Ethambutol 11 (78.6) 36 (85.7) 0.676
Streptomycin 4 (28.6) 23 (54.8) 0.126
Kanamycin 6 (42.9) 14 (33.3) 0.520
Capremycin 2 (14.3) 10 (23.8) 0.709
Ofloxacin 11 (78.6) 36 (85.7) 0.676
Moxifloxacin 9 (64.3) 23 (54.8) 0.756
Cycloserine 5 (35.7) 10 (23.8) 0.489
p-aminosalicylic
acid
7 (50.0) 21 (50.0) 1.000
Prothionamide 9 (64.3) 17 (40.5) 0.138
Abbreviations: TB Z tuberculosis; RFB Z rifabutin.
Values are number (%).
Rifabutin treatment for MDR-TB 29514.3%; p Z 0.106) (Table 5). Of 34 patients who attained
treatment success in both groups, no patients experienced
relapse during the median 21 months (range 4e49 months)
of follow-up.
Discussion
Although current guidelines recommend the limited use of
RFB in drug-susceptible TB for patients with acquired
immune deficiency syndrome or experienced intolerance to
RIF,6,7 the use of RFB in patients with MDR-TB has not yet
been described. Since some patients’ MDR-TB was suscep-
tible to RFB, this drug can be used in such cases, as is
supported by our findings. Our study supports the hypoth-
esis that RFB seem to be useful in the treatment of MDR-TB
as an additional drug in patients who have RFB-susceptible
MDR-TB infections.
To date, only a few studies have been conducted to
determine the effectiveness of a RFB-containing regimen in
MDR-TB.10,11 Bacteriological conversion was achieved in
34% among 270 patients in a study performed in five
nations,10 and Lee et al. reported that 47% of 43 patients
achieved sustained sputum conversion with a RFB-
containing regimen in Taiwan.11 However, as neither
study had a control group in order to compare the efficacy
of RFB, it was unclear whether the RFB-containing regimen
was more effective than conventional therapy that did notTable 4 Treatment modalities of 56 patients with MDR-TB.
Treatment modalities RFB gro
(n Z 14
No. of total TB drugs used 6 (5e8)
No. of drugs active against TB 4 (2e6)
No. of patients, treated with linezolid 4 (28.6)
No. of patients, surgical resection 2 (14.3)
Abbreviations: RFB Z rifabutin; TB Z tuberculosis.
Values are median (range) or number (%).use RFB for MDR-TB. Also, RFB susceptibility testing was
carried out in only few patients11 or was not done at all.10
Conversely, ours is the first study to use a control group to
better investigate the efficacy of a RFB-containing regimen.
In addition, we accurately classified the patients into two
groups on the basis of their DST results to RFB.
Although RFB, spiro-piperidyl-rifamycin derived from
rifamycin-S, is mainly used as a substitute for RIF in special
situations, the American Thoracic Society guidelines clas-
sify RFB as a first-line anti-TB drug.7 In addition the WHO
guidelines recently added RFB to group 1 drugs, the most
potent and best-tolerated anti-TB agents.16 RIF is an
essential component of TB treatment and has been referred
to as the most important anti-TB agent because of its
excellent sterilizing capacity.18 Considering that RFB is
more active than RIF against slow-growing mycobacteria,
including Mycobacterium tuberculosis,19,20 and that RFB
has a similar potency to RIF for the treatment of drug-
susceptible TB,9,21 the promising outcome we observed in
the RFB group is most likely related to the outstanding
potency of RFB against M. tuberculosis. In addition, most
patients tolerated RFB well in our study. If we had included
the single patient who had been excluded because of less
than one-month treatment with RFB in the RFB group, the
treatment success rate would be 86.7% (13/15) rather than
85.7% (12/14) in the RFB group.
Even though the median number of total prescribed
drugs and active drugs was significantly higher in the RFB
group, after excluding RFB, there was no significant
difference between the two groups in terms of the number
of total and active drugs. This suggests that the addition of
RFB may be the cause of the improved outcome in the RFB
group. Linezolid is classified as a group 5 drug by the WHO
guidelines,16 and Yew et al. reported its excellent efficacy
in the treatment of MDR-TB and XDR-TB.22 The rate of
linezolid use did not differ between the two groups in our
study and 10 patients in the RFB group achieved treatment
success without linezolid treatment, suggesting that
treatment success is unrelated to the use of linezolid.
We randomly chose age, sex, and drug resistance
pattern-matched control subjects in order to compare the
treatment outcomes between the treatment and control
groups. The treatment outcome in the control group was
similar to others reported in South Korea.5,23,24 XDR-TB has
proven much more difficult to treat making the drug
selection for XDR-TB is extremely difficult.16 While all five
patients with XDR-TB in the RFB group achieved treatment









Table 5 Treatment outcomes of 56 patients with MDR-TB.





Cure 10 (71.4) 19 (45.2) 0.126
Treatment completion 2 (14.3) 3 (7.1) 0.590
Failure 2 (14.3) 17 (40.5) 0.106
Transfer out 0 1 (2.4) 1.000
Default 0 1 (2.4) 1.000
Death 0 1 (2.4) 1.000
Treatment success 12 (85.7) 22 (52.4) 0.032
Abbreviations: RFB Z rifabutin.
Values are number (%).
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that RFB seems to be effective even in the treatment of
XDR-TB, if the organisms are susceptible to RFB.
More than 95% of RIF-resistant M. tuberculosis have
mutations in a hot-spot region of the RNA polymerase b-
subunit (rpoB) gene.25,26 The rpoB gene mutation is also
involved in resistance to RFB.26 While Uzun et al. reported
the high-level cross-resistance (88%) between RIF and
RFB,13 Senol et al. detected 73.1% cross-resistance in
Turkey27 and Chikamatsu et al. identified an overall cross-
resistance of 72.7% in Japan.28 In South Korea, the rate of
cross-resistance was 79.6% in one study14 and 70.5% in
another study.15 The rate of cross-resistance between two
drugs varies depending upon the mutation of the rpoB gene.
The RIF resistance-determining region (RRDR), composed of
an 81-bp nucleoside containing codons 507 through 533
within the rpoB gene, has been proposed as the most
frequently mutated region.25 Among these codons, muta-
tions at codons 526 and 531 are usually found in isolates of
M. tuberculosis resistant to both RIF and RFB,29 while
mutations at codons 516 and 522 are associated with
resistance to RIF, but only susceptibility to RFB.30 Our study
did not include any investigation into mutations of the
RRDR within the rpoB gene.
Mutation in the rpoB gene eventually leads to structural
change of ribonucleic acid (RNA) polymerase. Campbell
et al. reported that diverse mutations of the RRDR within
the rpoB gene are associated with the level of resistance to
RIF.31 That is, if certain mutation can cause significant
structural change at a site that is critical to RIF binding, it
can cause high-level resistance to RIF. On the other hand,
isolates remain susceptible to RIF if mutations make little
structural change to the RNA polymerase. Although there
have been no studies as to whether mutations at different
codons within rpoB gene affect binding of the RIF or RFB
differently to RNA polymerase owing to the difference of
structural change, we think that some mutations can cause
structural change to the RNA polymerase which permits
binding of only RFB, not RIF. This could be why RFB had
a therapeutic effect in a small proportion of patients with
MDR-TB with specific rpoB gene mutation patterns.
Although our findings suggest favorable treatment
outcomes of RFB-containing regimens, some limitations
should be considered. The most significant limitation of our
study was that it was conducted in a single referral center
and with a non-randomized, retrospective design thatincluded a relatively small number of patients. Further
studies with a better design and larger sample size are
needed to better determine the efficacy of RFB in the
treatment of MDR-TB and in order to generalize our findings
to a wider population of patients with MDR-TB.
Another limitation was that only about half of patients
with RFB-susceptible MDR-TB were treated with RFB, which
might induced a selection bias. The main reason why the
remaining 16 patients were not treated with RFB was the
fact they had already showed a favorable treatment
response to initial regimens that did not include RFB at the
time of their DST report. Therefore, the 15 RFB-treated
subjects could be more prone to a poor treatment response
than the 16 patients not treated with RFB, suggesting that
selection bias may not factor into the positive treatment
success rate in patients with RFB-susceptible MBR-TB.
Finally, in our study, HIV testing was conducted in only
five (8.9%) patients. One study reported the HIV prevalence
to be less than 0.1% in adults ages 15e49 years in South
Korea32 and Lee et al. showed only 77 (0.05%) of 152,887
patients with TB between 2001 and 2005 were confirmed to
have HIV.33 Since South Korea is a very low HIV-burden
country, doctors tend not to identify the possibility of HIV
infection in patients with MDR-TB or pulmonary TB.
Although the possibility of HIV infection is likely to be low in
our study population, the unknown HIV status of the
majority of our subjects should also be considered as
a significant limitation.
In summary, adding RFB to the treatment of patients
with RFB-susceptible MDR-TB resulted in a successful
outcome.
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